This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

In a quantitative modeling study, statins provided net benefit at higher 10-year risks for CVD than seen in most guidelines. The level of CVD risk at which net benefit occurs depends on age, sex, and statin type.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

The phase 3a PIONEER 6 trial met its primary endpoint, showing non-inferiority with regard to MACE, which was driven by a significant reduction in CV and all-cause mortality, compared to placebo, on top of standard care in T2DM.

Structural brain abnormalities are more common in patients with prediabetes compared with non-diabetics, and even more common in T2DM patients.

In diabetic patients at high cardio-renal risk, linagliptin was non-inferior to placebo in preventing CV outcomes, but led to slightly more renal outcomes compared with placebo.

In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.

ESC 2018 In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.

ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in individuals with moderate CV risk.